Incyte COVID-19 Response
Incyte takes public health very seriously, and we are closely monitoring the COVID-19 pandemic. Our primary focus is on ensuring patients have access to the medicines they need while safeguarding the health and safety of our employees.
See our responses to frequently asked questions below regarding how Incyte has responded to COVID-19. Please contact our support resources, listed below, for more information.
We encourage patients to first discuss any questions or concerns regarding their existing treatments with their healthcare providers, as they are best informed about the specific healthcare needs of their patients and the potential risks associated with discontinuing or modifying treatment.
In the United States, patients with questions can contact Incyte’s U.S. Medical Information line at 1-855-4-MEDINFO (1-855-463-3463) or send an email to firstname.lastname@example.org.
Eligible patients in the United States who are currently prescribed Jakafi® (ruxolitinib), Opzelura® (ruxolitinib) cream or Pemazyre® (pemigatinib) can contact IncyteCARES, a comprehensive program offering patient support, including financial assistance and ongoing education and resources for eligible patients.
More information about IncyteCARES is available by visiting www.incytecares.com or calling 1-855-4-Jakafi (855-452-5234).
Eligible patients in the United States who are currently prescribed Monjuvi® (tafasitamab-cxix) can contact My Mission Support, a robust patient support program offering financial assistance, ongoing education and other resources. For more information, please visit My Mission Support.